These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1410853)

  • 21. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
    Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
    Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenesis of secondary hyperparathyroidism.
    Slatopolsky E; Delmez JA
    Am J Kidney Dis; 1994 Feb; 23(2):229-36. PubMed ID: 8311080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of parathyroid hormone-dependent nephrocalcinosis by chronic administration of the organic phosphorothioate WR-2721.
    Hirschel-Scholz S; Caverzasio J; Bonjour JP
    Calcif Tissue Int; 1987 Feb; 40(2):103-8. PubMed ID: 3032378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on Mineral and Bone Disorders in Chronic Kidney Disease.
    Foster JD
    Vet Clin North Am Small Anim Pract; 2016 Nov; 46(6):1131-49. PubMed ID: 27436330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone growth during daily or intermittent calcitriol treatment during renal failure with advanced secondary hyperparathyroidism.
    Sanchez CP; He YZ
    Kidney Int; 2007 Sep; 72(5):582-91. PubMed ID: 17554252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy.
    Rodriguez M; Felsenfeld AJ; Llach F
    Kidney Int; 1991 Dec; 40(6):1063-8. PubMed ID: 1762307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperparathyroidism, glucose tolerance and platelet intracellular free calcium in chronic renal failure.
    Lu KC; Shieh SD; Lin SH; Chyr SH; Lin YF; Diang LK; Li BL; Sheu WH; Ding YA
    Q J Med; 1994 Jun; 87(6):359-65. PubMed ID: 8041868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of early allograft dysfunction with cinacalcet in a patient with nephrocalcinosis caused by severe hyperparathyroidism: a case report.
    Cheunsuchon B; Sritippayawan S
    BMC Res Notes; 2017 Apr; 10(1):153. PubMed ID: 28390426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ; González EA
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Calliada F; Marcelli D; Imbasciati E
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo assessments of calcium-regulated parathyroid hormone release in secondary hyperparathyroidism.
    Goodman WG; Belin TR; Salusky IB
    Kidney Int; 1996 Dec; 50(6):1834-44. PubMed ID: 8943464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenesis and medical treatment of secondary hyperparathyroidism.
    Fukagawa M; Kurokawa K
    Semin Surg Oncol; 1997; 13(2):73-7. PubMed ID: 9088062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical profile and outcome of primary hyperparathyroidism accompanied by chronic renal failure.
    Mizumoto D; Watanabe Y; Fukuzawa Y; Aoi N; Yamazaki C
    Clin Nephrol; 1994 Nov; 42(5):315-21. PubMed ID: 7851033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of endochondral bone formation: roles of growth hormone, 1,25-dihydroxyvitamin D and hyperparathyroidism.
    Sanchez CP
    Pediatr Nephrol; 2000 Jul; 14(7):646-9. PubMed ID: 10912535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxidative stress and chronic kidney disease.
    Brown SA
    Vet Clin North Am Small Anim Pract; 2008 Jan; 38(1):157-66, vi. PubMed ID: 18249247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcitriol in the management of secondary hyperparathyroidism of renal failure.
    Daisley-Kydd RE; Mason NA
    Pharmacotherapy; 1996; 16(4):619-30. PubMed ID: 8840368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus.
    Bover J; Jara A; Trinidad P; Rodriguez M; Felsenfeld AJ
    Bone; 1999 Sep; 25(3):279-85. PubMed ID: 10495131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcium and phosphorus homeostasis in dogs with spontaneous chronic kidney disease at different stages of severity.
    Cortadellas O; Fernández del Palacio MJ; Talavera J; Bayón A
    J Vet Intern Med; 2010; 24(1):73-9. PubMed ID: 19925576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular basis for the management of secondary hyperparathyroidism in chronic renal failure.
    Fukagawa M; Yi H; Fukuda N; Kurokawa K
    Artif Organs; 1995 Dec; 19(12):1210-4. PubMed ID: 8967876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.